What is SIGNOS?
Signos is at the forefront of weight care, integrating continuous glucose monitoring (CGM) with an intelligent, data-driven recommendation application. This unique combination is engineered to facilitate healthy and sustained weight loss for its users. The company's approach leverages real-time physiological data to provide personalized insights and actionable guidance, positioning it as a significant player in the digital health and wellness sector. The recent enterprise-level funding underscores the market's confidence in Signos' innovative model for tackling chronic health challenges through technology.
How much funding has SIGNOS raised?
SIGNOS has raised a total of $77M across 2 funding rounds:
Series A
$13M
Series B
$20M
Series A (2021): $13M with participation from GV
Series B (2023): $20M led by Cheyenne Ventures and Samsung NEXT
Key Investors in SIGNOS
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, consumer products, and frontier technology innovations.
Cheyenne Ventures
Cheyenne Ventures Inc operates in the Construction industry, employing 10-19 people with revenues between $5M-$10M. The company is headquartered in Oklahoma City, Oklahoma.
Samsung NEXT
Samsung NEXT, founded in 2012, provides software and services to complement Samsung's global hardware footprint, combining product development, investment, M&A, and partnerships.
What's next for SIGNOS?
With the recent major strategic investment, Signos is poised for significant expansion and further development of its platform. This capital injection is expected to fuel advancements in their recommendation engine, enhance user engagement features, and potentially broaden their market reach. The company's focus on combining CGM technology with app-based guidance suggests a strategic direction towards personalized, data-informed health management solutions. This funding round, classified as Series B, indicates a transition from early-stage development to a scaling phase, aiming to solidify its market position and drive sustained growth in the competitive digital health landscape.
See full SIGNOS company page
